Chimeric Therapeutics is trading A$0.01 (-8.33%) amid unexplained selling or a delayed reaction.
- No verified company-specific announcement or trading halt was identified for September 3, 2026.
- The latest material disclosure, dated August 19, 2026, said CHM-2101 enrolment stopped after dose-limiting toxicities, while funding and going-concern risks remained uncertain.
- Biotech-sector strength does not explain the decline.